Division of Critical Care Medicine, Department of Pediatrics, Children's National Health System, George Washington University School of Medicine and Health Sciences, Washington, DC.
Division of Biomedical Informatics, George Washington University School of Medicine and Health Sciences, Washington, DC.
Pediatr Crit Care Med. 2020 Sep;21(9):e599-e609. doi: 10.1097/PCC.0000000000002351.
To describe the pharmaceutical management of sedation, analgesia, and neuromuscular blockade medications administered to children in ICUs.
A retrospective analysis using data extracted from the national database Health Facts.
One hundred sixty-one ICUs in the United States with pediatric admissions.
Children in ICUs receiving medications from 2009 to 2016.
EXPOSURE/INTERVENTION: Frequency and duration of administration of sedation, analgesia, and neuromuscular blockade medications.
Of 66,443 patients with a median age of 1.3 years (interquartile range, 0-14.5), 63.3% (n = 42,070) received nonopioid analgesic, opioid analgesic, sedative, and/or neuromuscular blockade medications consisting of 83 different agents. Opioid and nonopioid analgesics were dispensed to 58.4% (n = 38,776), of which nonopioid analgesics were prescribed to 67.4% (n = 26,149). Median duration of opioid analgesic administration was 32 hours (interquartile range, 7-92). Sedatives were dispensed to 39.8% (n = 26,441) for a median duration of 23 hours (interquartile range, 3-84), of which benzodiazepines were most common (73.4%; n = 19,426). Neuromuscular-blocking agents were dispensed to 17.3% (n = 11,517) for a median duration of 2 hours (interquartile range, 1-15). Younger age was associated with longer durations in all medication classes. A greater proportion of operative patients received these medication classes for a longer duration than nonoperative patients. A greater proportion of patients with musculoskeletal and hematologic/oncologic diseases received these medication classes.
Analgesic, sedative, and neuromuscular-blocking medications were prescribed to 63.3% of children in ICUs. The durations of opioid analgesic and sedative medication administration found in this study can be associated with known complications, including tolerance and withdrawal. Several medications dispensed to pediatric patients in this analysis are in conflict with Food and Drug Administration warnings, suggesting that there is potential risk in current sedation and analgesia practice that could be reduced with practice changes to improve efficacy and minimize risks.
描述 ICU 中儿童镇静、镇痛和神经肌肉阻滞药物的药物管理。
使用从国家数据库 Health Facts 中提取的数据进行的回顾性分析。
美国 161 个 ICU 中有儿科住院患者。
接受 2009 年至 2016 年药物治疗的 ICU 患儿。
暴露/干预:镇静、镇痛和神经肌肉阻滞药物的使用频率和持续时间。
在中位年龄为 1.3 岁(四分位距,0-14.5)的 66443 名患者中,63.3%(n=42070)接受了非阿片类镇痛药、阿片类镇痛药、镇静剂和/或神经肌肉阻滞剂治疗,包括 83 种不同的药物。58.4%(n=38776)使用了阿片类和非阿片类镇痛药,其中非阿片类镇痛药的处方占 67.4%(n=26149)。阿片类镇痛药的中位使用时间为 32 小时(四分位距,7-92)。39.8%(n=26441)使用镇静剂的中位时间为 23 小时(四分位距,3-84),其中苯二氮䓬类最常见(73.4%;n=19426)。17.3%(n=11517)使用神经肌肉阻滞剂的中位时间为 2 小时(四分位距,1-15)。所有药物类别中,年龄越小,持续时间越长。手术患者比非手术患者接受这些药物治疗的时间更长。患有肌肉骨骼和血液/肿瘤疾病的患者接受这些药物治疗的比例更高。
63.3%的 ICU 患儿接受了镇痛、镇静和神经肌肉阻滞剂治疗。本研究中发现的阿片类镇痛药和镇静药物的使用时间可能与已知的并发症有关,包括耐受和戒断。在这项分析中,给儿科患者开出的几种药物与食品和药物管理局的警告相冲突,这表明目前的镇静和镇痛实践存在潜在风险,可以通过改变实践以提高疗效和最小化风险来降低风险。